PharmaTelevision - Gallus BioPharmaceuticals: Mark Bamforth talks about saving jobs, local support and the importance of finding the right investment partners.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Gallus BioPharmaceuticals: Mark Bamforth talks about saving jobs, local support and the importance of finding the right investment partners.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Mark Bamforth, President and CEO of Gallus BioPharmaceuticals.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Foundation and facilities of Gallus BioPharmaceuticals

Fintan Walton:

Hello and welcome to PharmaTelevisionNews Review here at BIO-Europe in Duesseldorf, Germany 2011. On this show I have Mark Bamforth, who is President and CEO of a company called Gallus BioPharmaceuticals based in St. Louis in States, welcome.

Mark R. Bamforth:

Thank you.

Fintan Walton:

Mark, you've got a story about the foundation of Gallus BioPharmaceuticals company could you tell us that story?

Mark R. Bamforth:

Certainly, Fintan I was working for a large biotech company one of the top five for over 20-years, I was running a global manufacturing organization as well as a contract manufacturing business and the facility that I acquired to start Gallus BioPharmaceuticals was a facility owned by Centocor a division of Johnson & Johnson and I had actually become familiar with that facility because I had tried to acquire it twice from my previous employer and both times it didn't work out for reasons that aren't particularly important, but through that time I got to know the facility well, the leadership team there, the work forces in place, the capabilities of the facility and the potential of the facility and that really gave me an idea that here was an opportunity to start a business really to take a site a satellite of a large pharmaceutical company to repurpose it as a contract manufacturing organization based on the long history of that site has had of making biopharmaceutical products.

Fintan Walton:

Okay, now obviously to do something that you needed to raise the capital you needed to bring a number of people along with you in the mission to buy this facility, so if you just tell us a little bit about that story?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Mark R Bamforth

President

At the time of recording this PTV interview Mark R. Bamforth is the President and CEO of Gallus BioPharmaceuticals. Mark founded Gallus BioPharmaceuticals in 2010 in order to establish the premier contract manufacturer of commercial bulk biologics with a team which is currently delivering commercial products to patients in over 50 countries from an approved facility in the USA. In this leadership role, Mark draws upon his extensive experience of assembling talented teams to build and operate manufacturing plants around the world as well as his business experience as a Corporate Officer and business leader at Genzyme Corporation during a period of rapid growth. Mark was SVP for Corporate Operations and Pharmaceuticals at Genzyme Corporation with responsibility for 12 manufacturing sites in USA and Europe with 3600 staff. During the past decade, he oversaw a 200% growth in operations with the investment of over $2B in multiple technologies for manufacturing and infrastructure as Genzyme grew organically and through acquisitions. Additionally, Mark was responsible for the Pharmaceutical business which delivered a doubling in revenue over 5 years by performing contract manufacturing of peptides, lipids, custom materials and drug delivery technologies to the pharmaceutical industry and manufacturing materials for internal drug programs. Prior to joining Genzyme in 1988, Mark was a chemical engineer in the Scottish whisky industry where he led a JV biotech project to produce a nutraceutical from algae and designed and operated a patented photo-bioreactor. Mark serves on the MassBio Board, representing the biotech industry in MA, and has served on advisory boards for University College London's school of Biochemical Engineering and on Scottish Enterprise's International Advisory Board. Mark is a Founding Trustee of a charity, the Saltire Foundation, which offers young Scottish entrepreneurs the opportunity to experience and learn in high growth companies in the USA and beyond. Mark has a BS in Chemical Engineering from Strathclyde University, Glasgow, and an MBA from Henley Business School.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Gallus BioPharmaceuticals

Gallus BioPharmaceuticals is a premier biologics contract manufacturing organization based in St. Louis, MO. Gallus operates an FDA-approved, commercially-certified facility formerly owned by Johnson & Johnson's Centocor division. The Gallus facility has capabilities for mammalian cell culture and protein purification in both perfusion and fed batch mode and is being expanded to offer additional development and clinical services capabilities. The plant currently produces two leading commercial biologics products, distributed globally.